<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129202</url>
  </required_header>
  <id_info>
    <org_study_id>Stable</org_study_id>
    <nct_id>NCT05129202</nct_id>
  </id_info>
  <brief_title>Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases</brief_title>
  <official_title>Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastasesï¼šA Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with non-small cell lung cancer may have brain metastases after receiving&#xD;
      immunotherapy, but the therapeutic effect has not been clear. This trial aims to explore the&#xD;
      efficacy and the control of immune checkpoint inhibitors in non small cell lung cancer&#xD;
      patients with brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Actual">September 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>November 2017- October 2021</time_frame>
    <description>disease remission rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>November 2017- October 2021</time_frame>
    <description>progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>November 2017- October 2021</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy alone or chemotherapy combined with anti-angiogenesis</arm_group_label>
    <description>patients with Chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>immuntherapy</arm_group_label>
    <description>patients with immune checkpoint inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immune therapy</intervention_name>
    <description>The patient receives immunotherapy</description>
    <arm_group_label>immuntherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with brain metastasis received immunotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis&#xD;
             3. Treated with ICIs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Patients with a clear driver mutation that can be targeted for first-line treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang C Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang C Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>7+861383123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nong Yang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>yangnong0217@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>yangnong0217@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>Director, Head of Medical Oncology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

